Antiplatelet therapy in coronary heart disease.
D000244:Adenosine Diphosphate / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000097:blood / Q000517:prevention & control; D001241:Aspirin / Q000627:therapeutic use; D001792:Blood Platelets / Q000187:drug effects* / Q000502:physiology; D002561:Cerebrovascular Disorders / Q000097:blood / Q000517:prevention & control; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy* / Q000517:prevention & control; D004837:Epinephrine / Q000627:therapeutic use; D011464:Epoprostenol / Q000037:antagonists & inhibitors; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000517:prevention & control; D010973:Platelet Adhesiveness / Q000187:drug effects; D010974:Platelet Aggregation / Q000187:drug effects; D011433:Propranolol / Q000627:therapeutic use; D013928:Thromboxane A2 / Q000037:antagonists & inhibitors
D013928:Thromboxane A2; D000244:Adenosine Diphosphate; D011433:Propranolol; D011464:Epoprostenol; D001241:Aspirin; D004837:Epinephrine